title: The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
abstract: Potential vaccine strategies against otitis media are to prevent (1) symptomatic infections in the middle ear and/or (2) carriage of pneumococci and thereby subsequent middle ear infections. The possibility of using immunity to virulence proteins of pneumococci to elicit immunity against pneumococci has been examined. PspA has been found to have efficacy against otitis media in animals. Vaccination with a mixture of PsaA and PspA has been observed to offer better protection against nasal carriage in mice, than vaccination with either protein alone. PspA and pneumolysin have been shown to elicit protection against invasive infections. The inclusion of a few of these proteins into the polysaccharide-protein conjugate vaccines may be able to enhance their efficacy against otitis media and might be able to constitute a successful all-protein pneumococcal vaccine.
authors.affiliation: Department of Microbiology, University of Alabama at Birmingham (UAB), Birmingham, AL 35294-2170, USA. dbriles@uab.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Briles
authors.forename: S K
authors.initials: SK
authors.lastname: Hollingshead
authors.forename: G S
authors.initials: GS
authors.lastname: Nabors
authors.forename: J C
authors.initials: JC
authors.lastname: Paton
authors.forename: A
authors.initials: A
authors.lastname: Brooks-Walter
mesh_terms: D018829:Adhesins, Bacterial; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology*; D016667:Bacterial Capsules / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology*; D002353:Carrier State / Q000276:immunology / Q000517:prevention & control; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D005544:Forecasting; D006801:Humans; D007107:Immune System / Q000254:growth & development; D007223:Infant; D008074:Lipoproteins; D026901:Membrane Transport Proteins; D051379:Mice; D009305:Nasopharynx / Q000382:microbiology; D010033:Otitis Media / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D045331:Photosystem I Protein Complex; D011008:Pneumococcal Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D051381:Rats; D013296:Streptococcus pneumoniae / Q000145:classification / Q000276:immunology*; D013301:Streptolysins / Q000276:immunology*; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology
chemical_list: D018829:Adhesins, Bacterial; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D008074:Lipoproteins; D026901:Membrane Transport Proteins; D045331:Photosystem I Protein Complex; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; C085000:PsaA protein, Streptococcus; D013301:Streptolysins; D018074:Vaccines, Conjugate; C032290:plY protein, Streptococcus pneumoniae; C051592:pneumococcal surface protein A